Teslenko O. S., Tovazhnyanska O. L.

THE ROLE OF BRAIN-DERIVED NEUROTROPHIC FACTOR AND INTERLEUKIN-6 IN THE FORMATION OF COGNITIVE IMPAIRMENTS IN PATIENTS WITH MULTIPLE SCLEROSIS

---

Show/Download

About the author:

Teslenko O. S., Tovazhnyanska O. L.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

This study analysed the relationship between levels of brain-derived neurotrophic factor (BDNF) and pro-inflammatory interleukin-6 (IL-6) and cognitive impairment in patients with multiple sclerosis (MS) with different disease durations. The study included 72 patients with relapsing-remitting MS, who were divided into three groups depending on the duration of the disease: Group 1 - 27 patients with a disease duration of up to 5 years, Group 2 - from 5 to 10 years (23 patients), Group 3 - over 10 years (22 patients). The neurocognitive status of patients was assessed using the MoCA, SDMT and PASAT-3 tests, and the serum levels of BDNF and IL-6 were determined by enzyme-linked immunosorbent assay. The results showed that in patients with MS, the formation of cognitive impairment (as assessed by the MoCA, SDMT, and PASAT-3 scores) was associated with a decrease in serum BDNF and an increase in IL-6 levels. In particular, a positive correlation was found between BDNF levels and cognitive test scores (MoCA r=0.61, p=0.000; SDMT r=0.668, p=0.000 and PASAT-3 r=0.634, p=0.000), while IL-6 levels were negatively correlated with cognitive scores (MoCA r=-0.417, p=0.000; SDMT r=-0.532, p=0.000 and PASAT-3 r=-0.415, p=0.000). These results confirm the importance of neurotrophic and inflammatory dysfunction in the development of cognitive impairment in patients with MS.

Tags:

Bibliography:

1. Dobson R, Giovannoni G. Multiple sclerosis - a review. European Journal of Neurology. 2019;26(1):27-40. DOI: 10.1111/ene.13819.
2. Shulha OD, Chabanova AS, Kotsyuba OH. Rozsiyanyi skleroz v Ukrayini. Ukrayinskyi medychnyi chasopys. 2023;1(153):63-66. DOI: 10.32471/umj.1680-3051.153.237930. [in Ukrainian].
3. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, et al. Inflammation in multiple sclerosis: The good, the bad, and the complex. Lancet Neurol. 2002;1:499-509. DOI: 10.1016/S1474-4422(02)00223-5.
4. Yamout BI, Alroughani R. Multiple Sclerosis. Seminars in Neurology. 2018;38(2):212-225. DOI: 10.1055/s-0038-1649502.
5. Nociti V, Romozzi M. The Role of BDNF in Multiple Sclerosis Neuroinflammation. International journal of molecular sciences. 2023;24(9):8447. DOI: https://doi.org/10.3390/ijms24098447.
6. Nociti V. What is the role of Brain-derived neurotrophic factor in Multiple Sclerosis neuroinflammation? Neuroimmunol. Neuroinflamm. 2020;7:291-299. DOI: 10.20517/2347-8659.2020.25.
7. Teslenko OS, Tovazhnyanska OL. Klinichni osoblyvosti kohnityvnoyi dysfunktsiyi u patsiyentiv z retsydyvno-remituyuchym typom rozsiyanoho sklerozu. Visnyk Kharkivskoho natsionalnoho universytetu imeni V.N. Karazina. Seriya «Medytsyna». 2024;32(1(48)):28-39. DOI: https://doi.org/10.26565/2313-6693-2024-48-03. [in Ukrainian].
8. Meca-Lallana V, Gascón-Giménez F, Ginestal-López RC, Higueras Y, Téllez-Lara N, Carreres-Polo J, et al. Cognitive impairment in multiple sclerosis: diagnosis and monitoring. Neurological Sciences. 2021;42(12):5183-5193. DOI: 10.1007/s10072-021-05165-7.
9. Trenova AG, Slavov GS, Manova MG, Aksentieva JB, Miteva LD, Stanilova SA. Cognitive Impairment in Multiple Sclerosis. Folia Medica (Plovdiv). 2016;58(3):157-163. DOI: 10.1515/folmed-2016-0029.
10. Kalb R, Beier M, Benedict, RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Sclerosis. 2018;24(13):1665-1680. DOI: 10.1177/1352458518803785.
11. Cortés-Martínez A, Matias-Guiu JA, Pytel V, Montero P, Moreno-Ramos T, Matías-Guiu J. What is the meaning of PASAT rejection in multiple sclerosis? Acta Neurologica Scandinavica. 2019;139(6):559-562. DOI: 10.1111/ane.13090.
12. Riccitelli GC, Pagani E, Rodegher M, Colombo B, Preziosa P, Falini A, et al. Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 2019;25(2):204-216. DOI: 10.1177/1352458517743091.
13. Dagenais E, Rouleau I, Demers M, Jobin C, Roger E, Chamelian L, et al. Value of the MoCA test as a screening instrument in multiple sclerosis. Canadian Journal of Neurological Sciences. 2013;40(3):410-415. DOI: 10.1017/s0317167100014384.
14. Freitas S, Batista S, Afonso AC, Simões MR, de Sousa L, Cunha L, et al. The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis. Applied Neuropsychology: Adult. 2018;25(1):57-70. DOI: 10.1080/23279095.2016.1243108.
15. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 2015;15:545-558. DOI: 10.1038/nri3871.
16. Patanella AK, Zinno M, Quaranta D, Nociti V, Frisullo G, Gainottiet G, et al. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res. 2010;88(5):1106- 1112. DOI: 10.1002/jnr.22276.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 2, 173, 263-273 pages, index UDC 616.832-004.2:616.89-008.46/.47]-078

DOI:

10.29254/2077-4214-2024-2-173-263-273